[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367147-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367147-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cgassting-signaling-pathway-in-gynecological-malignancies-from-molecular-mechanisms-to-therapeutic-values","cGAS/STING signaling pathway in gynecological malignancies - From molecular mechanisms to therapeutic values","","A review analyzes how the cGAS/STING innate-immune DNA-sensing pathway shapes gynecological cancer biology and therapy outcomes. It explains dual effects in cervical, ovarian, and endometrial malignancies, including promotion of antitumor immunity versus facilitation of immune evasion. The review links cGAS/STING activity to tumor microenvironments, immune surveillance, and inflammation, emphasizing molecular mechanisms that govern cancer progression. It also evaluates therapeutic strategies such as STING agonists, PARP inhibitors, and targeted immunotherapies, including approaches to counter tumor-mediated immune suppression.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cgassting-signaling-pathway-in-gynecological-malignancies-from-molecular-mechanisms-to-therapeutic-values/367147/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cgassting-signaling-pathway-in-gynecological-malignancies-from-molecular-mechanisms-to-therapeutic-values/367147.png","ImageObject",300,407,{"name":42,"@type":43},"Aria","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does the cGAS/STING pathway play in innate immunity?","Question",{"text":63,"@type":64},"It detects cytosolic DNA from pathogens or cellular damage, triggering type I interferons and inflammatory cytokines to initiate immune responses.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does cGAS/STING influence gynecological cancers?",{"text":68,"@type":64},"It can either promote antitumor immunity or facilitate tumor immune evasion, affecting tumor microenvironments and immune surveillance in cervical, ovarian, and endometrial cancers.",{"name":70,"@type":61,"acceptedAnswer":71},"Which therapeutic strategies are reviewed in relation to cGAS/STING?",{"text":72,"@type":64},"The review covers STING agonists, PARP inhibitors (PARPi), and targeted immunotherapies, describing how these approaches can enhance immune responses and help overcome chemotherapy resistance and tumor-mediated immune suppression.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367147,1790538892,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","TYPE Review  \nPUBLISHED 30 January 2025  \nDOI 10.3389/fimmu.2025.1525736  \nOPEN ACCESS  \nEDITED BY  \nKristin Huntoon,  \nUniversity of Arizona, United States  \nREVIEWED BY  \nDeeptashree Nandi,  \nJohns Hopkins University, United States Mateo Sokaˇc,  \nAlgebra University, Croatia  \n*CORRESPONDENCE  \nBingxue Zhang  \n [bingxuez093@gmail.com](bingxuez093@gmail.com)  \nRECEIVED 10 November 2024  \nACCEPTED 09 January 2025  \nPUBLISHED 30 January 2025  \nCITATION  \nZhang D and Zhang B (2025) cGAS/STING signaling pathway in gynecological malignancies: From molecular mechanisms to therapeutic values.  \nFront. Immunol. 16:1525736 .  \ndoi: 10.3389/fimmu.2025.1525736  \nCOPYRIGHT  \n© 2025 Zhang and Zhang. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \ncGAS/STING signaling pathway in gynecological malignancies:  \nFrom molecular mechanisms to therapeutic values  \nDanyang Zhang and Bingxue Zhang*  \nDepartment of Obstetrics, The First Hospital of China Medical University, Shenyang, Liaoning, China  \nGynecological cancers, including cervical, ovarian, and endometrial malignancies, remain a signiﬁcant global health burden, exacerbated by disparities in access to preventive measures such as HPV vaccination and routine screening. The cGAS/STING signaling pathway, a pivotal mechanism in innate immunity, detects cytosolic DNA from pathogens or cellular damage, triggering immune responses via type I interferons and inﬂammatory cytokines. This pathway’s dual role in gynecological cancers, either promoting antitumor immunity or facilitating tumor immune evasion, makes it a compelling target for innovative therapies. The article outlines cGAS/STING ’s inﬂuence on tumor microenvironments, immune surveillance, and inﬂammation, with emphasis on molecular mechanisms driving cancer progression. It explores interactions between DNA damage response pathways and immune modulation, highlighting the impact of cGAS/STING activation or suppression in ovarian, cervical, and endometrial cancers. The therapeutic potential of STING agonists, PARP inhibitors, and targeted immunotherapies is reviewed, demonstrating how these approaches can boost immune responses, counteract chemotherapy resistance, and improve patient outcomes. The study also discusses strategies for leveraging c GAS/STING signaling to enhance the efﬁca cy of immunotherapies and address tumor-mediated immune suppression, providing insights into future directions for personalized cancer treatments.  \nKEYWORDS  \nDNA damage response, cGAS, immunotherapy, cervical cancer, ovarian cancer, endometrial cancer, STING, PARPi  \nIntroduction  \nIn 2022, cervical, ovarian, and endometrial cancers remained the most prevalent gynecological cancers worldwide. Cervical cancer, strongly linked to HPV, had a higher impact in regions with lower scores on the Human Development Index (HDI), a measure assessing levels of health, education, and income, where limited access to HPV vaccines and  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nroutine screening contribute to elevated incidence and mortality rates (1, 2) . Ovarian cancer, meanwhile, was more frequent in higher-HDI regions, as was endometrial cancer, which also had a notable presence in these areas. These differences reﬂect signiﬁcant gaps in preventive services and early detection, emphasizing the need for global initiatives to reduce mortality, especially in areas with fewer resources (3) . Identifying new signaling pathways and immunetargeted strategies in gynecological cancer therapy is crucial because these approaches address the limitations of existing","cbCaim5nL9AX0kPH","https://ap.wps.com/l/cbCaim5nL9AX0kPH","pdf",6740628,26,"English","# Introduction\n# cGAS/STING pathway in gynecological cancers\n## Dual roles in antitumor immunity and immune evasion\n# Therapeutic implications\n## STING agonists and combinational strategies\n## PARP inhibitors and targeted immunotherapies\n# Future directions","[{\"question\":\"What role does the cGAS/STING pathway play in innate immunity?\",\"answer\":\"It detects cytosolic DNA from pathogens or cellular damage, triggering type I interferons and inflammatory cytokines to initiate immune responses.\"},{\"question\":\"How does cGAS/STING influence gynecological cancers?\",\"answer\":\"It can either promote antitumor immunity or facilitate tumor immune evasion, affecting tumor microenvironments and immune surveillance in cervical, ovarian, and endometrial cancers.\"},{\"question\":\"Which therapeutic strategies are reviewed in relation to cGAS/STING?\",\"answer\":\"The review covers STING agonists, PARP inhibitors (PARPi), and targeted immunotherapies, describing how these approaches can enhance immune responses and help overcome chemotherapy resistance and tumor-mediated immune suppression.\"}]","cGAS/STING signaling pathway in gynecological malignancies - From molecular mechanisms to therapeutic values | PDF",1790169470,66,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/914df2b9bb8a6d73be580f754362c95e.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a236ade08a18afbcc4247a4facc635a2.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a98acf8bc615370eeb1be2e0589333d.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/12fce928b271ec48f93b1cd23470dff6.webp",980,1385]